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Open aSummary
Background: Currently, there are no studies of well-characterized severe asthmatics in Brazil.
We aimed to study a population of severe treated asthmatics still uncontrolled to characterize
them and define possible phenotypes.
Methods: Descriptive cross-sectional outpatient study of severe asthmatics, evaluating func-
tional and inflammatory markers, health-related quality of life, anxiety and depression symp-
toms, clinical control status, and characteristics related to atopy, age of asthma onset,
induced sputum eosinophil levels, and airflow limitation. We also grouped the subgroups
characteristics to identify phenotypes. The study is registered on ClinicalTrial.gov NCT
01089322.
Results: From 128 eligible patients with severe/uncontrolled asthma, 74 fulfilled the inclu-
sion criteria. The cohort was comprised of 85% women, frequently with a body mass index
higher than 31 kg m2, atopy (60%), early-onset disease (50%), sputum eosinophilia (80%), co-
morbidities, and reduced quality of life. Nonatopics had significant higher asthma onset
(19 y.a.) and twice level of induced sputum eosinophil. Late-onset patients had significantly
less atopy (57%) and higher levels of induced sputum eosinophils. Non-eosinophilics had lower
levels of inflammatory markers. Patients with airflow limitation had more intensive care unit
admissions (56%) and 1.5 times more airway resistance. Subgroups characteristics identified
a priori four well-characterized phenotypes, with 55% presenting sputum eosinophilia.s de Carvalho Aguiar, 44, Piso dos Ambulato´rios, Sala B-7 Cerqueira Ce´sar, CEP 05403-900, Sa˜o Paulo,
incor.usp.br (R.M. de Carvalho-Pinto), pnealberto@incor.usp.br (A. Cukier), lucieneangelini@usp.br
sp.br (L. Antonangelo), tmauad@usp.br (T. Mauad), maridol@usp.br (M. Dolhnikoff), k.f.rabe@kh-
telmach@incor.usp.br (R. Stelmach).
ccess under the Elsevier OA license.
48 R.M. de Carvalho-Pinto et al.Conclusion: Our data emphasize the high burden of disease, the persistence of inflammation
and the existence of clinical possible phenotypes population sharing common features with
published cohorts. Despite the necessity of further investigation into pathogenic mecha-
nisms, this study with clinically difficult patient group may help to improve future asthma
care.
ª 2011 Elsevier Ltd. Open access under the Elsevier OA license.Background
Many clinical studies have demonstrated the efficacy of
adequate asthma treatment in reducing symptoms and
exacerbations, improving health-related quality of life
(HRQoL) and lung function, achieving asthma control,1
controlling airway inflammation,2 and reducing mortality
rates.3 However, 5%e10% of asthmatics do not achieve
clinical control despite having an accurate diagnosis,
receiving proper medication, and adhering to treatment
plans. Within this group, severe asthmatics clearly experi-
ence the greatest HRQoL impairment4 and represent
a significant proportion of health care costs.5
Brazil has the sixth highest asthma prevalence in the
world,6 but the prevalence of severe asthma in this pop-
ulation is unknown. The lack of national, large-scale asthma
management programs and limited access to medication for
many years are probably related to this information gap.
In 2005, the Brazilian government implemented
a nationwide asthma program that provides free access to
medication for patients with doctor-diagnosed severe
asthma. This program greatly impacted asthma control and
treatment adherence,7 improved HRQoL,8 decreased health
care utilization (HCU),9 reduced morbidity,8 and lowered
overall health care system and family costs.8,10,11
Over the last decade, several international cohort
studies4,5,12 have demonstrated severe asthmatics’ char-
acteristics and shown that a group of factors, including
atopy, age of disease onset, duration of disease, and
comorbidities,13 are possible determinants of the different
phenotypes observed in persistent severe asthma patients.
The current research thus aims to improve phenotype
characterization12 to increase our understanding of disease
pathogenesis and help to tailor effective therapies.
Brazilians have varied genetic and environmental back-
grounds, and asthma proper regular treatment has histori-
cally been different from treatment in the so far published
American and European cohorts. Because of the current
lack of studies characterizing the clinical features, risk
factors, and phenotype distribution of severe asthma in
Brazil, we present herein the clinical, functional and
inflammatory characteristics of a severe asthmatic pop-
ulation and describe comorbidities and aggravating factors.
We also attempt to identify clinical subgroups and possible
phenotypes that could be shared with similar populations
around the world.
Methods
The local institutional review board approved this study,
and all patients provided written informed consent. Thestudy is registered on ClinicalTrial.gov as NCT 01089322.
This is a cross-sectional descriptive study. The participants
were recruited from 2500 asthma patients from several
regions of Sa˜o Paulo, who registered at the outpatient
asthma clinic of a university hospital. This population was
75% female, 75% Caucasian and 15% of African descent. The
average monthly family income of 55% of the patients was
less than US$380. At our asthma center, patients diagnosed
with asthma have free access to anti-inflammatory thera-
pies and educational programs.
Inclusion criteria
Based on previous studies,4,5 the inclusion criteria for severe
asthmapatientswere (a) 18e65 years old; (b) diagnosedwith
asthma by a specialist and treated for more than 1 year,
according to Global Initiative for Asthma (GINA) guidelines14;
(c) airway reversibility documentedwithin 5 years before the
start of the study using at least one of the following criteria:
an FEV1 increase  12% of predicted (and a 200-ml increase)
after 400mg of salbutamol, an FEV1 increase of at least 400ml
after prednisolone 0.5 mg/kg/day for 14 days or, in patients
with FEV1  70% of predicted, a methacholine-positive
hyper-responsiveness challenge with a cut-off value of
PD20 < 2490 mg; (d) treatment with 1000 mg/day of
beclomethasone or equivalent; (e) daily use of a long-acting
beta2 agonist (LABA); (f) at least one asthma exacerbation in
the last year that required an oral corticosteroid burst; and
(g) smokers, non-smokers or ex-smokers of 30 pack-years.
If the patient was a smoker, asthma symptoms must have
been present before the onset smoking, and cigarette use
could not exceed 10 per day.
Exclusion criteria
Patients were excluded if they had any respiratory tract
infection within 4 weeks prior to inclusion in the study, had
another active or chronic pulmonary disorder, were preg-
nant or had any clinically significant disease that could
interfere with the results.
Clinical data and questionnaires
The Asthma Control Questionnaire (ACQ)15 and Asthma
Control Test (ACT)16 were used to evaluate the level of
asthma control. HRQoL was measured using St. George’s
Respiratory Questionnaire (SGRQ)17 and the SF-36 Ques-
tionnaire, Medical Outcomes Study 36-Item Short Form
Health Survey (SF-36).
Depression symptoms were evaluated according to the
Beck Depression Inventory (BDI),18 and anxiety symptoms
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(STAI).19
Patients were divided according to age of asthma onset
(either early onset (<12 years old) or late onset (12 years
old)) as described earlier.13
Pulmonary function
Spirometry was performed according to ATS/ERS guide-
lines.20 European Coal and Steel Community (ECSC)
prediction equations were used.21 Lung volumes were
measured with a body plethysmograph.22 Reversibility was
assessed 20 min after the inhalation of 400 mg of salbuta-
mol. Persistent airflow obstruction was expressed as post-
bronchodilator FEV1 or FEV1/FVC < 75% predicted. Carbon
monoxide-diffusing capacity (DLCO) was measured using
a single-breath technique (Elite DX e Medical Graphics
Corporation, St. Paul, MN; USA), and exhaled carbon
monoxide concentration (COex) was measured using a Micro
CO Meter device (Micro Medical Ltd., Rochester, RU). The
cut-off value of COex for non-smokers was <6 ppm.23
Atopy
Prick tests for common aeroallergens (mites, fungi, pollen,
and dog and cat fur) were performed. The test was
considered positive when at least one antigen-induced
reaction was 3 mm in diameter greater than the negative
control (saline solution) as measured 15 min after the
puncture.24 Patients with at least one positive prick test
were categorized as atopic. Total serum IgE was deter-
mined using a fluorescence enzyme immunoassay.
Inflammatory markers
Sputum induction (IS) was performed as previously
described.25 Eosinophil-positive (EOSþ) patients were
defined as those with induced sputum eosinophils 3%, and
eosinophil-negative (EOS) patients had eosinophil levels
<3%.26 Exhaled nitric oxide (FeNO) was collected using an
offline system following published guidelines,27 and its
concentration was determined using chemiluminescence
with a properly calibrated Siervers analyzer (Model NOA
280, Siervers Instruments, Inc.).128 eligible 
33 (25.8%) did not assigne
informed consent 
21 (16.4%) did not  
meet inclusion criteria 
74 (57.8%)  
 included 
Figure 1 Flow chart showing the numStatistical analysis
Continuous variables are presented as means  SD or
medians (CI: 25%e75%), and categorical variables are pre-
sented as both a number and percentage. ManneWhitney
and t tests were used to compare continuous variables
between groups: atopic vs. nonatopic, early vs. late onset,
eosinophilic vs. non-eosinophilic, and persistent vs. non-
persistent airflow limitation. Categorical variables were
compared using chi-square (c2) or Fisher tests. Pearson’s or
Spearman’s correlation tests were used to analyze variable
correlations. p < 0.05 was considered statistically signifi-
cant. All analyses were performed using the SPSS v. 16.0
statistical package for Windows (SPSS Inc., Chicago, IL,
USA) and Sigma Stat v. 3.5 (Systat Inc., AL).Results
One hundred twenty-eight eligible patients with severe
asthma that was non-controlled despite proper treatment
(approximately 5.1% of the outpatient asthma clinic data-
base) were referred for the study. Of these, 74 (57.8%)
patients fulfilled our study’s inclusion criteria (Fig. 1).
The patients’ demographic and clinical characteristics
are shown in Table 1. There was a higher prevalence of
women than men. Forty-one (55%) patients were obese
(BMI  30 kg m2), and 33 (80%) were female. All of the
patients had been using inhaled corticosteroids plus LABA
for at least 4 years (CI 3.34e4.17). The COex values were
low, meaning that none of the patients were current
smokers. A skin prick test was performed for 69 patients
and was positive for 44 (63.8%) patients: 30 (68.2%) reacted
positively only to mites, 2 (4.5%) only to fungi and 12
(27.3%) to both mites and fungi. None of our patients was
using antihistamines. IgE levels were 509.6  539 UI/mL.
Sixty-seven (90.5%) patients had been hospitalized at
least once for an asthma exacerbation, and 47 (63%) had
reported 5 hospitalizations. Twenty-five (34%) had been
hospitalized at least once in the year prior to our study,
while 37 (50%) had required ICU (intensive care unit)
admission due to an exacerbation and 28 (38%) reported an
episode of intubation. Spirometry, body plethysmography,
and FeNO data are shown in Table 2.d   
- Age >65 years = 7  
- No BD response = 4 
- Presence of comorbidities = 8 
- Pregnant = 1 
- Ex-smoker (65 packyears) = 1 
ber of patients in each category.
Table 1 Demographic and clinical characteristics.
Variable n Z 74
Age, yra 44.5  10.7
Gender (% female) 77
BMI kg/m2 a 30.0  6.2
Age of asthma onset, yr; b 9 (1e22)
Asthma duration, yra 31.5  15.8
Time without adequate treatment, yra 27.7  15.9
Smoking status (never/ex) n (%) 53 (71.6)/21 (28.4)
Pack year,b 2.8 (3.7e10)
ICs dose, mcg/da 1394  337
OCs use, n (%) 20 (27)
SABA, puff.daya 5  3
Leukotriene receptor antagonist, n (%) 31(41.9)
exCO, ppma 4.9  1.9
Data are reported as means  SD unless otherwise indicated;
BMI: body mass index; ICs: Inhaled corticosteroid; OCs: Oral
corticosteroid; SABA: Short acting beta agonist: exCO: Exhaled
carbon monoxide concentration.
a Data are represented as mean  SD.
b Data are represented as median (CI 25%e75%).
Table 3 Induced sputum.
Total count cell ( 106 cells/mL) 0.88  1.08
Neutrophils % 51.4  19.6
Eosinophils % 16.5  16.4
Macrophages % 13.4  10.5
Lymphocytes % 3.3  3.6
Bronchial Epithelial cells % 15.3  15.9
Squamous Cell Contamination % 5  7.8
Viability % 72.4  16.2
Data are reported as means  SD.
Table 4 Asthma Control Test, Asthma Control Question-
naire, SGRQ, SF-36, IDATE and BECK questionnaires.
ACT, points (n Z 74) 11.7  4.5
ACQ, points (n Z 69) 3.2  1.1
SGRQ scores
Symptoms 63  18
Activity 80  17
Impact 64  14
Total 67  14
SF-36 scores
50 R.M. de Carvalho-Pinto et al.Sixty-seven (90.5%) patients were able to produce an IS
sample (Table 3). There was a correlation between FeNO
and IS eosinophils (Pearson’s r Z 0.279, p Z 0.022).
Table 4 lists the scores for asthma control, HRQoL, and the
anxiety and depression questionnaires. The asthma control
evaluation showed that 93.2% of the patients were non-
controlled based on ACQ (>1.57) and ACT (19) values, and
we observed a significant correlation between ACQ and ACT
scores (Pearson’s r Z 0.777, p < 0.001). There was also
a significant association between FEV1% and ACQ (Pearson’s
r Z 0.390, p Z 0.001) and ACT scores (r Z 0.303,
p Z 0.009). All SGRQ domains, especially the total score,Table 2 Pulmonary function.
Parameters
FVC (L) (n Z 74)a 2.68  0.72
FVC, % predicted (n Z 74)a 74  15
FEV1 (L) (n Z 74)
a 1.58  0.52
FEV1, % predicted (n Z 74)
a 54  18
FEV1/FVC (n Z 74)
a 59  13
BD % (n Z 74)a 16  16
TLC, % predicted (n Z 60)b 109  13
RV/TLC, % predicted (n Z 60)b 159  31
Raw, % predicted (n Z 55)b 282  126
Gaw, % predicted (n Z 55)b 24  12
DLCO, % predicted (n Z 57) 103  24
FeNO, ppb (n Z 74) 33.4  17.6
Data are reported as means  SD. FVC: Forced Vital Capacity;
FEV1: Forced Expiratory Volume in first second; BD: Broncho-
dilator response; TLC: Total Lung Capacity; RV: Residual
Volume; Raw: Airway Resistance; Gaw: Airway complacence;
DLCO: Carbon Monoxide-Diffusing Capacity; FeNO: Exhaled nitric
oxide.
a According to references 20,21.
b According to reference 22.showed a correlation with both ACQ (rZ 0.566, p < 0.001)
and ACT scores (rZ 0.541, p < 0.001). The physical func-
tion (r Z 0.462 and r Z 0.470, p < 0.001), physical role
(r Z 0.330 and r Z 0.448, p < 0.001) and vitality
(rZ 0.380 and rZ 0.410, p < 0.001) domains of the SF-36
also correlated with ACQ and ACT scores, respectively. The
majority of patients displayed moderate anxiety, and one
third showed signs of moderate depression.
There was a high frequency of aggravating factors and
comorbidities with 72% of patients reporting rhinosinusitisPhysical function 34.9  22.9
Physical role 25.4  31.4
Body pain 39.4  22.5
General health 40.5  19.8
Vitality 40.8  20.2
Social function 54.4  26.8
Emotional aspects 32.4  42.2
Mental health 50.1  22.9
IDATE (n Z 70) 36.6  9.2
IDATE score  30, n (%) 57 (81)
IDATE score  50, n (%) 6 (8.5)
BecK (n Z 70) 16.2  11.7
BecK score 19, n (%) 22 (31)
BecK score 30, n (%) 8 (11)
ACT: Asthma Control Test; ACQ: Asthma Control Questionnaire;
SGRQ: St. George Respiratory Questionnaire; SF-36: SF-36
Questionnaire, Medical Outcomes Study 36 e Item Short Form
Health Survey; IDATE: State-Trait Anxiety Inventory; Beck: Beck
Depression Inventory; ACT  19 points: non-controlled asthma;
ACQ > 1.57: non-controlled asthma; SGRQ score ranges from
0 to 100: a lower score represents a better HRQoL; SF-36:
a higher score represents a better HRQoL; IDATE score: 30
pointsZ moderate anxiety; 50 pointsZ severe anxiety; Beck
maximum score is 63 points: 10e18 points Z mild depression;
19e29 points Z moderate; 30 points Z severe.
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disease (GERD). The patients were already being treated
for these conditions. Asthma symptoms with aspirin intake
were present in 19%, and symptoms worsened during
menstruation in 22% of females.
Baseline characteristics divided by subgroups are shown
in Tables 5 and 6. Nonatopic patients tended to be older
than atopics and had a higher asthma onset age and
a higher level of IS eosinophils. The late-onset subgroup had
significantly fewer ICU admissions and lower percentages of
positive prick tests than the early-onset group (Table 5). We
also observed a statistically significant inverse correlation
between ACT and ACQ scores (r Z 0.78, p < 0.01) in the
late-onset subgroup. There was a higher prevalence of
patients in the EOSþ subgroup, but no differences were
observed compared with the EOS group except for
significantly higher FeNO values in EOSþ patients. There
was a correlation between IS eosinophils and FeNO in the
EOSþ subgroup (r Z 0.318, p < 0.01). Patients with
persistent airflow limitation had significantly more ICU
hospitalizations and higher airway resistance (Table 6).
There were no significant differences reported among the
comparison groups for the presence of rhinosinusitis, GERD,
anxiety and depression symptoms, or for BDI and STAI
scores.
Next, we produced an arbitrary hierarchy of the inter-
relations of genotypic (atopy), clinical (asthma onset age),
inflammatory (IS eosinophils) and functional (persistent or
non persistent airflow limitation) characteristics. Sixty-
three (91.3%) patients had all data and could be grouped
into four possible phenotypes as demonstrated in Fig. 2.
The major group (24.6% of patients) included atopic
patients with early-onset asthma, EOSþ and persistent
airflow limitation. The second group (15.9%) included non-
atopics, late-onset asthma, EOSþ and persistent airflow
limitation. The third group (14.5%) consisted of patients
with atopic characteristics, late-onset asthma, EOSþ and
persistent airflow limitation, and the fourth group (7.2%)
included nonatopics, early-onset asthma, EOS and
persistent airflow limitation. We also identified a miscella-
neous group (1e3 patients per group) with mixed charac-
teristics, including classic asthmatics (3 [4.3%] of patients)
with atopy, early-onset asthma, EOSþ and non-persistent
airflow limitation.Discussion
In the present study, we describe the clinical, functional,
and inflammatory characteristics of a severe asthmatic
adult population in Brazil. The group was predominately
female and displayed frequent atopy, high average BMI,
early disease onset, presence of several comorbidities
(particularly anxiety), and elevated burden of disease as
evidenced by the frequency of hospitalization and
a reduced HRQoL. The patients displayed elevated sputum
eosinophils despite using high doses of inhaled cortico-
steroids. Although these patients had been receiving
regular treatment for at least four years, they failed to
achieve full clinical asthma control and continued to have
persistent airflow limitation. Non-adherence to treatment
is always a problem to consider, even when patients arefollowed for an extended period. Subgroup analyses
showed that nonatopic patients had higher levels of
sputum eosinophils than atopics. Patients with early-onset
asthma tended to be more atopic and had more ICU
admissions than did the late-onset group. In addition,
EOSþ patients had higher FeNO values, and the persistent
airflow limitation subgroup had more ICU admissions and
greater airway resistance. Based on the subgroups’ char-
acteristics, we identified 4 a priori phenotypes that
included 62.2% of well-described patients. In contrast to
published European4 and American12 studies on severe
asthma, in which patients were recruited from various
centers, our severe asthma patients were followed by
pulmonary specialists in one tertiary university hospital
where they received treatment and medication free of
charge based on asthma management guidelines. Inter-
estingly, the 5.1% prevalence of severe asthmatics in our
population is similar to those reported in other studies.5
Our population of severe asthma patients came from
various sociocultural backgrounds and lived in environ-
ments different from those described in previous studies.
Most importantly, these patients had not received regular
treatment for their asthma for extended periods since the
disease’s onset. Nevertheless, this population shares
several clinical characteristics with previously reported
cohorts of severe asthma patients in the developed
world.4,12
The female predominance observed in our patient group
was reported in the European cohort4 but not in the
American cohort,12 suggesting that severe asthma could be
a gender-related disease.4 We do, however, concede that
this observation could result from a selection bias4
because, on average, women attended medical visits
more regularly than men.
Obesity affects approximately 7.4% of the adult female
population in Sa˜o Paulo. A high average BMI has been
associated with severe asthma4 and was observed both in
our population and in the Enfumosa study.4 Although
mechanisms linking both conditions are still poorly under-
stood, there is evidence that obesity impairs clinical
control.5 However, we did not find any significant BMI
differences in the subgroups analyzed.
Although atopy has previously been considered a less
important predisposing disease severity factor when
compared with infections,28 the percentage of positive
prick tests in our patients was similar to the positive
percentage reported in international studies4,12 and rep-
resented fewer positive tests than those from mild and
moderate asthmatics in other cohorts.12
Hospitalizations account for the largest share of asthma-
related health care costs,5 and programs based on providing
no-cost medication to severe asthmatics have been shown
to lead to a reduction in overall hospital admissions.9,29 In
our study, hospitalization rates were still high and were
similar to those seen in other severe asthma cohorts. We
did find that our patients had fewer hospitalizations during
the year prior to our study, which may be attributed to their
access to free medication. We also found a high percentage
of ICU admissions and the need for intubation in our patient
group. Prior studies found that more than 40% of severe
asthmatics had been admitted to the ICU, and approxi-
mately 10%5e20% required intubation.12
Table 5 Demographic and clinical characteristics divided by subgroups.
Atopic
(n Z 44) (64%)
Non-atopic
(n Z 25) (36%)b
Early-onset
(n Z 39) (53%)
Late-onset
(n Z 35) (47%)
Age, yc, g 42.5  11.2 47.6  9.6 43.8  10.8 45.3  10.6
Gender (F/M) (%)d 84/16 68/32 72/28 83/17
BMI, kg/m2c, g 29.2  5.9 31.8  6.5 30  6.7 30.3  5.8
Asthma onset age, ye, h 4.5 (1e17) 19 (1e33)a 1 (1e2) 25 (17e33)b
Asthma duration, yc, g 32.5  13.5 29.8  19.3 42.1  10.9 19.6  11.4b
ACQ scorec, g 3.19  1.5 3.21  1.0 3.27  1.15 3.13  1.05
ACT scorec, g 12  4.5 11.5  4.5 11.5  4.7 12  4.3
Hospitalization last year, n (%)d 15 (34) 10 (40) 36 (92.3) 32 (91.4)
ICU hospitalization, n (%)f 14 (32) 9 (36) 27 (54) 16 (46)b
FEV1, % predicted
c, g 54  19 51  16 54  19 54  17
FEV1/FVC
c, g 67  13 66  14 65  13 68  12
BD %c, g 16.7  16.0 14.2  15.9 13.4  13.8 18.5  17.7
RV/TLC, % predictedc, g 159  35 (n Z 33) 160  26 (n Z 23) 161  32 (n Z 27) 155  30 (n Z 30)
Raw, % predictedc, g 279  122 (n Z 31) 280  139 (n Z 21) 293  135 (n Z 27) 272  117 (n Z 28)
ICs dose (mg day1)c, g 1395  354 1400  316 1432  335 1321  306
OCs, n (%)d 9 (28) 4 (20) 13 (33) 7 (20)
IgE (UI/mL)e, h 405 (164e741) 220 (65e643) 369 (135e738) 295 (167e696)
Sputum eosinophils, %e, h 9 (3.5e22) 18 (5e32)a 7 (2e27) 12 (5.3e28.7)
Sputum neutrophils, %c, g 55  19 46  19 54  20 49  18
FeNO (ppb)c, g 34.1  18.8 31.9  15.6 31.3  18.7 35.2  16.2
Prick test positive, n (%)d 44 (100) 0 (0) 27 (69) 20 (57)b
ICU: Intensive Care Unit; FEV1: Forced expiratory volume in 1 s; FEV1/FVC: Forced expiratory volume in 1 s/Forced vital capacity ratio;
RV/TLC: Residual volume/total lung capacity ratio; Raw: Airway resistance; ICs: Inhaled corticosteroid; OCs: Oral corticosteroid; IgE:
Imunoglobulin E; FeNO: Exhaled nitric oxide. BD: Bronchodilator response.
a p < 0.05.
b p < 0.001.
c t Test.
d Fisher test.
e ManneWhitney test.
f c2 test.
g Are presented as mean  SD.
h Are presented as median (CI 25%e75%).
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comorbidities,12,30 and it has been shown that treating
these accompanying disorders can improve clinical asthma
control.31,32 Rhinosinusitis and GERD contribute to uncon-
trolled asthma, but, because our patients were receiving
regular treatments for both these conditions, they may not
be directly linked to the lack of asthma control.
In contrast to previous Brazilian cohorts,7e9,11,30,33 this is
the first study of a well-characterized severe population
treated regularly and sufficiently enough to control their
asthma. Of note in this context is the fact that these patients
had a long disease history with irregular treatment periods
with amaximum treatment time of 50% of their asthma lives.
Currently, there is little information on the natural
progression of severe asthma. One possibility, as least in
our patients, is that the absence of routine asthma treat-
ments for extended periods contributed to the develop-
ment of severe asthma by remodeling the patient’s airway,
which was suggested by abnormal functional values. To
validate this hypothesis, further and more invasive studies
of disease pathology in these individuals is necessary to
determine the extent of airway structural changes.
The patients’ inability to take physical and emotional
control of the disease clearly impacts their lives andprobably causes increased levels of anxiety and depres-
sion. The values obtained on the SGRQ were comparable to
those of our severe COPD patients34 and were almost
double those of mild to moderate asthma patients and
elderly COPD patients.35 Low HRQoL was not associated
with poor lung function (FEV1 %), but was correlated with
poor asthma control (ACT and ACQ scores) and depression
symptoms. The evaluation of depression and anxiety
symptoms is recommended in asthmatics, as these symp-
toms heavily influence HRQoL scores.36 HRQoL can be used
as an objective measurement of the personal burden of
asthma, independent of pulmonary function changes. Most
of our patients exhibited mood disorders, such as anxiety
and depression, which are associated with noncompliance,
poor asthma control, increased HCU, near-fatal asthma
attacks, and mortality.37 Thus, mood evaluation represents
one area of potential intervention in patients with severe
asthma.
Although the patients had severe asthma, their lung
function abnormalities were moderate. However, their high
residual volume/total lung capacity ratio values suggest an
air-trapping component that is associated with the most
severe forms of asthma.38 The higher rate of ICU hospital-
ization among the persistent airflow limitation subgroup of
Table 6 Demographic and clinical characteristics divided by subgroups.
EOSþ
(n Z 53) (79%)
EOS
(n Z 14) (21%)b
No persistent airflow
limitation
(n Z 13) (18%)
Persistent airflow
limitation
(n Z 61) (82%)b
Age, yc, g 43.9  10.7 44.3  11.3 39.5  8.8 45.6  10.8
Gender (F/M) (%)d 79/21 57/43 9/4 47/14
BMI, kg/m2c, g 29.5  6.3 31.9  6.7 28.7  5.4 30.5  6.4
Asthma onset age, ye, h 12 (1e26) 1.5 (1e10) 8 (1e25) 10 (1e23)
Asthma duration, yc, g 29.8  16.2 35.9  14.8 25.3  14.1 32.8  16.0
ACQ scorec, g 3.22  1.11 3.04  1.22 2.75  1.00 3.30  1.10
ACT scorec, g 11.8  4.8 12  3.8 12.2  3.7 11.6  4.7
Hospitalization last year,
n (%)d
49 (92.5) 13 (92.8) 4 (31) 20 (33)
ICU hospitalization,
n (%)f
26 (49) 7 (50) 3 (23) 34 (56)a
FEV1, % predicted
c, g 53  17 59  18 75  10 49  15b
FEV1/FVC
c, g 67  13 66  14 75  7 65  13b
BD %c, g 15.5  15.1 14.2  18.6 14.1  14.3 16.2  16.3
RV/TLC, % predictedc, g 159  33 (n Z 44) 157  33 (n Z 10) 141  37 (n Z 10) 163  29 (n Z 50)a
Raw, % predictedc, g 277  134 (n Z 42) 268  71 (n Z 9) 193  78 (n Z 9) 299  126 (n Z 46)a
ICs dose (mg day1)c, g 1393  343 1440  337 1477  413 1377  321
OCs, n (%)d 16 (30) 4 (28) 2 (15) 18 (30)
IgE (UI/mL)e, h 304 (159e686) 459 (131e745) 537 (259e903) 292 (143e668)
Sputum eosinophils, %e, h 15 (6.7e31.2) 1 (1e2)b 19 (6e40) 9 (4e25)
Sputum neutrophils, %c, g 50  18 56  26 44  17 53  20
FeNO (ppb)c, g 36.2  18.8 22.9  7.5a 34.1  18.3 33.6  17.7
Prick test positive, n (%)d 35 (66) 8 (57) 10 (77) 37 (61)
ICU: Intensive Care Unit; FEV1: Forced expiratory volume in 1 s; FEV1/FVC: Forced expiratory volume in 1 s/Forced vital capacity ratio;
RV/TLC: Residual volume/total lung capacity ratio; Raw: Airway resistance; ICs: Inhaled corticosteroid; OCs: Oral corticosteroid; IgE:
Immunoglobulin E; FeNO: Exhaled nitric oxide. BD: Bronchodilator response; EOSþ: Eosinophil-positive; EOS: Eosinophil-negative.
a p < 0.05.
b p < 0.001.
c t Test.
d Fisher test.
e ManneWhitney test.
f c2 test.
g Are presented as mean  SD.
h Are presented as median (CI 25%e75%).
Figure 2 Patients (%) subdivided by possible phenotypic characteristics according to atopy, asthma onset age, induced sputum
eosinophils and airflow limitation.
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54 R.M. de Carvalho-Pinto et al.our cohort reinforces this notion. Our functional results
indicated fixed changes in the peripheral airway and
possible airway remodeling. Persistent airflow limitation
despite effective asthma treatment has been associated
with adult-onset asthma, increased airway hyper-
responsiveness, and sputum eosinophilia.39 These findings
highlight the need to evaluate the degree of small airway
alterations in severe asthma patients.
Most of the patients in this relatively homogeneous
cohort of severe asthmatics presented sputum eosinophilia
despite receiving steroid treatments. Persistent eosino-
philia is a characteristic of some severe asthma subgroups40
but, in our study, was not related to any specific clinical
characteristic or to the ICS dose used. The higher preva-
lence of chronic oral corticosteroid use among atopic
patients could explain the lower eosinophilic inflammation
in this group, although both variants of the disease (atopic
and nonatopic) may be associated with bronchial mucosal
eosinophilic inflammation. The normalization of sputum
eosinophilia after an intramuscular corticosteroid trial
suggests that some severe asthmatics required additional
anti-inflammatory treatment to improve airway inflamma-
tion.41 Our data suggest the need to follow these patients
with a maximum anti-inflammatory treatment and objec-
tive measures of adherence and response.
Most studies of severe asthma have identified the age of
asthma onset and atopy as two of the most consistently
reproducible clinical phenotypes.12,13 Although we
acknowledge that the number of patients included in this
study is small, we identified a priori several clinically
defined subgroups.
Remarkably significant differences were found when
patients were divided according to atopy, with nonatopic
patients presenting high sputum eosinophilia. Early-onset
asthmatics were more atopic and had a higher number of
ICU admissions than late-onset asthmatic patients despite
having similar baseline FEV1 and sputum eosinophil levels.
The greater ICU rate in this group is probably related to the
longer asthma duration. Patients with persistent airflow
limitations also had higher ICU admission rates, which may
be due to significant lung function impairment. In the EOSþ
subgroup, the only distinct feature we observed was
significantly higher FeNO levels. This finding may indicate
that the use of a 3% cut-off to classify patients as
eosinophil-positive or -negative was not ideal for this
cohort, although it is widely used in the literature. And also
indicate that eosinophils are not particularly relevant in
this severe disease asthma cohort. Another point of note
concerns the fact that the small number of patients in the
EOS subgroup may have affected these results. Other than
the controversial findings regarding FeNO values and
asthma severity,12 FeNO measurements can generally be
used to identify EOSþ individuals among patients whose
severe asthma remains uncontrolled despite improved
treatment.42
Recently, the aspects related to the burden of non-
controlled severe asthma were discussed and some
perspectives were proposed with a special focus on low-
and middle-income countries.43 The authors highlighted the
need for researchers to characterize phenotypes and
search for specific risk factors and associated comorbid-
ities. We identified four possible phenotypes that includeda substantial number of the patients in our cohort. The
largest group included most typical asthma characteristics
other than persistent airflow limitation, suggesting the
possibility of airway remodeling, which is compatible with
severe asthma. The second group included nonatopic and
late-onset patients who nonetheless exhibited eosinophilic
inflammatory characteristics (EOSþ) and persistent airflow
limitation. The smallest group differed from the others
specifically in the absence of eosinophilic inflammation.
Three quarters of the patients from the well-characterized
(no miscellaneous) groups shared the same inflammatory
pattern and persistent airflow limitation independent of
atopic characteristic and asthma onset age, suggesting that
corticosteroids should be the therapeutic management
target in these patients to avoid future functional impair-
ment. Only 62.2% of our patients could be classified into
one of the four subgroups using the predefined patterns,
suggesting that the miscellaneous group should be classified
better using cluster analysis.
Our study does, however, contain some limitations. This
research is a cross-sectional study with a small number of
patients from a single center and a tertiary university
hospital, and part of the comorbidity information and HCU
relies on historical data. Tobacco use may be considered
a confounding factor, as it is related to persistent airflow
obstruction and lower corticosteroid response. However, less
than one third of our patients were proven ex-smokers.
Perhaps they represent an overlap between asthma and
COPD/chronic bronchitis.Conclusion
We have described a cohort of severe asthma patients
derived from a large clinical database from an academic
hospital in Sa˜o Paulo, Brazil. These patients share a series
of common features with other published cohorts from
around the world and emphasize the high burden of
disease, the persistence of inflammation, and the existence
of clinical phenotypes. This cross-sectional analysis will be
followed by controlled intervention trials and longitudinal
observations. Further research into the specific character-
istics of this cohort could uncover an understanding of the
pathology and pathogenic mechanisms of severe asthma.
This is the first study to characterize a clinically difficult
patient group, and these findings may improve future
asthma care in Brazil.Acknowledgments
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